Literature DB >> 9249200

In-vitro studies of two 5-nitroimidazole derivatives.

M Castelli1, M Malagoli, A I Ruberto, A Baggio, C Casolari, C Cermelli, M R Bossa, T Rossi, F Paolucci, S Roffia.   

Abstract

This paper reports the findings obtained using two new compounds belonging to the 5-nitroimidazole family: sulphuridazole (V1) and sulphonidazole (V2). We first assessed their antimicrobial activity on Clostridia spp. and then extended the study to Gram-positive and Gram-negative aerobic microorganisms and to Candida albicans. Their MICs were compared with those of metronidazole. The findings show that the antibacterial and antimycotic activity of sulphonidazole is greater than that of sulphuridazole, while metronidazole is not active against any aerobic organism. It also emerges that the NO2 group is indispensable for all the microorganisms assayed and that sulphuridazole and sulphonidazole are the first two 5-nitroimidazoles active against C. albicans. The redox potentials of the 5-nitroimidozoles studied suggest that their action mechanism is mainly based on redox processes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249200     DOI: 10.1093/jac/40.1.19

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  1 in total

1.  Metronidazole decreases viability of DLD-1 colorectal cancer cell line.

Authors:  Anna Sadowska; Rafał Krętowski; Beata Szynaka; Marzanna Cechowska-Pasko; Halina Car
Journal:  Cancer Biother Radiopharm       Date:  2013-06-18       Impact factor: 3.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.